Targeting von Willebrand factor as a novel anti-platelet therapy; Application of ARC1779, an Anti-vWF aptamer, against thrombotic risk

详细信息    查看全文

• 作者：Ok-Nam Bae (1) (2)
  
• 刊名：Archives of Pharmacal Research
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：35
• 期：10
• 页码：1693-1699
• 全文大小：823KB
• 参考文献：1. Arzamendi, D., Dandachli, F., Th茅or锚t, J. F., Ducrocq, G., Chan, M., Mourad, W., Gilbert, J. C., Schaub, R. G., Tanguay, J. F., and Merhi, Y., An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an / ex vivo shear-induced arterial thrombosis. / Clin. Appl. Thromb. Hemost., 17, E70鈥揈78 (2011). CrossRef
  2. Barrett, N. E., Holbrook, L., Jones, S., Kaiser, W. J., Moraes, L. A., Rana, R., Sage, T., Stanley, R. G., Tucker, K. L., Wright, B., and Gibbins, J. M., Future innovations in anti-platelet therapies. / Br. J. Pharmacol., 154, 918鈥?39 (2008). CrossRef
  3. Blann, A. D., Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. / Thromb. Haemost., 95, 49鈥?5 (2006).
  4. Bongers, T. N., de Maat, M. P., van Goor, M. L., Bhagwanbali, V., van Vliet, H. H., G贸mez Garc铆a, E. B., Dippel, D. W., and Leebeek, F. W., High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. / Stroke, 37, 2672鈥?677 (2006). CrossRef
  5. Bouchard, P. R., Hutabarat, R. M., and Thompson, K. M., Discovery and development of therapeutic aptamers. / Annu. Rev. Pharmacol. Toxicol., 50, 237鈥?57 (2010). CrossRef
  6. Cataland, S. R., Peyvandi, F., Mannucci, P. M., L盲mmle, B., Kremer Hovinga, J. A., Machin, S. J., Scully, M., Rock, G., Gilbert, J. C., Yang, S., Wu, H., Jilma, B., and Knoebl, P., Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. / Am. J. Hematol., 87, 430鈥?32 (2012). CrossRef
  7. Cauwenberghs, N., Meiring, M., Vauterin, S., van Wyk, V., Lamprecht, S., Roodt, J. P., Nov谩k, L., Harsfalvi, J., Deckmyn, H., and Kotz茅, H. F., Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. / Arterioscler. Thromb. Vasc. Biol., 20, 1347鈥?353 (2000). CrossRef
  8. Chen, L., Bracey, A. W., Radovancevic, R., Cooper, J. R., Jr., Collard, C. D., Vaughn, W. K., and Nussmeier, N. A., Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. / J. Thorac. Cardiovasc. Surg., 128, 425鈥?31 (2004). CrossRef
  9. Clemetson, K. J. and Clemetson, J. M., Platelet GPIb complex as a target for anti-thrombotic drug development. / Thromb. Haemost., 99, 473鈥?79 (2008).
  10. Cosmi, B., ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. / Curr. Opin. Mol. Ther., 11, 322鈥?28 (2009).
  11. Davi, G. and Patrono, C., Platelet activation and atherothrombosis. / N. Engl. J. Med., 357, 2482鈥?494 (2007). CrossRef
  12. De Meyer, S. F., Stoll, G., Wagner, D. D., Kleinschnitz, C., De Meyer, S. F., Stoll, G., Wagner, D. D., and Kleinschnitz, C., / Stroke, 43, 599鈥?06 (2012). CrossRef
  13. Diener, J. L., Daniel Lagass茅, H. A., Duerschmied, D., Merhi, Y., Tanguay, J. F., Hutabarat, R., Gilbert, J., Wagner, D. D., and Schaub, R., Inhibition of von Willebrand factormediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. / J. Thromb. Haemost., 7, 1155鈥?162 (2009). CrossRef
  14. Firbas, C., Siller-Matula, J. M., and Jilma, B., Targeting von Willebrand factor and platelet glycoprotein Ib receptor. / Expert Rev. Cardiovasc. Ther., 8, 1689鈥?701 (2010). CrossRef
  15. Gawaz, M., Langer, H., and May, A. E., Platelets in inflammation and atherogenesis. / J. Clin. Invest., 115, 3378鈥?384 (2005). CrossRef
  16. Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., Boufakhreddine, S., Holohan, T. V., and Schaub, R. G., First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. / Circulation, 116, 2678鈥?686 (2007). CrossRef
  17. Gresele, P., Momi, S., and Falcinelli, E., Anti-platelet therapy: phosphodiesterase inhibitors. / Br. J. Clin. Pharmacol., 72, 634鈥?46 (2011). CrossRef
  18. He, S., Cao, H., Magnusson, C. G., Eriksson-Berg, M., Mehrkash, M., Schenck-Gustafsson, K., and Blomb盲ck, M., Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein. / Thromb. Res., 103, 241鈥?48 (2001). CrossRef
  19. Huang, R. H., Fremont, D. H., Diener, J. L., Schaub, R. G., and Sadler, J. E., A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. / Structure, 17, 1476鈥?484 (2009). CrossRef
  20. Jackson, S. P. and Schoenwaelder, S. M., Anti-platelet therapy: in search of the 鈥榤agic bullet鈥? / Nat. Rev. Drug Discov., 2, 775鈥?89 (2003). CrossRef
  21. Jilma, B., Paulinska, P., Jilma-Stohlawetz, P., Gilbert, J. C., Hutabarat, R., and Kn枚bl, P., A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. / Thromb. Haemost., 104, 563鈥?70 (2010). CrossRef
  22. Jilma-Stohlawetz, P., Gilbert, J. C., Gorczyca, M. E., Kn枚bl, P., and Jilma, B., A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. / Thromb. Haemost., 106, 539鈥?47 (2011a). CrossRef
  23. Jilma-Stohlawetz, P., Gorczyca, M. E., Jilma, B., Siller-Matula, J., Gilbert, J. C., and Kn枚bl, P.., Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. / Thromb. Haemost., 105, 545鈥?52 (2011b). CrossRef
  24. Jilma-Stohlawetz, P., Kn枚bl, P., Gilbert, J. C., and Jilma, B. B., The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. / Thromb. Haemost., 108, 284鈥?90 (2012). CrossRef
  25. Keefe, A. D. and Schaub, R. G., Aptamers as candidate therapeutics for cardiovascular indications. / Curr. Opin. Pharmacol., 8, 147鈥?52 (2008). CrossRef
  26. Kiefer, T. L. and Becker, R. C., Inhibitors of platelet adhesion. / Circulation, 120, 2488鈥?495 (2009). CrossRef
  27. Kn枚bl, P., Jilma, B., Gilbert, J. C., Hutabarat, R. M., Wagner, P. G., and Jilma-Stohlawetz, P., Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. / Transfusion, 49, 2181鈥?185 (2009). CrossRef
  28. Lenting, P. J., Pegon, J. N., Groot, E., and de Groot, P. G., Regulation of von Willebrand factor-platelet interactions. / Thromb. Haemost., 104, 449鈥?55 (2010). CrossRef
  29. Mackman, N., Triggers, targets and treatments for thrombosis. / Nature. 45, 914鈥?18 (2008). CrossRef
  30. Markus, H. S., McCollum, C., Imray, C., Goulder, M. A., Gilbert, J., and King, A., The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. / Stroke, 42, 2149鈥?153 (2011). CrossRef
  31. Mayr, F. B., Knobl, P., Jilma, B., Siller-Matula, J. M., Wagner, P. G., Schaub, R. G., Gilbert, J. C. and Jilma-Stohlawetz, P., The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura / ex vivo. / Transfusion, 50, 1079鈥?087 (2010). CrossRef
  32. Michelson, A. D., Anti-platelet therapies for the treatment of cardiovascular disease. / Nat. Rev. Drug Discov., 9, 154鈥?69 (2010). CrossRef
  33. Nesbitt, W. S., Westein, E., Tovar-Lopez, F. J., Tolouei, E., Mitchell, A., Fu, J., Carberry, J., Fouras, A. and Jackson, S. P., A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. / Nat. Med., 15, 665鈥?73 (2009). CrossRef
  34. Nichols, W. L., Hultin, M. B., James, A. H., Manco-Johnson, M. J., Montgomery, R. R., Ortel, T. L., Rick, M. E., Sadler, J. E., Weinstein, M., and Yawn, B. P., von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). / Haemophilia, 14, 171鈥?32 (2008). CrossRef
  35. Noris, P. and Balduini, C. L., Investigational drugs in throm botic thrombocytopenic purpura. / Expert Opin. Investig. Drugs, 20, 1087鈥?098 (2011). CrossRef
  36. Raju, N. C., Eikelboom, J. W. and Hirsh, J., Platelet ADPreceptor antagonists for cardiovascular disease: past, present and future. / Nat. Clin. Pract. Cardiovasc. Med., 5, 766鈥?80 (2008). CrossRef
  37. Rayes, J., Hommais, A., Legendre, P., Tout, H., Veyradier, A., Obert, B., Ribba, A. S., and Girma, J. P., Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. / J. Thromb. Haemost., 5, 321鈥?28 (2007). CrossRef
  38. Reininger, A. J., VWF attributes 鈥?impact on thrombus formation. / Thromb. Res., 122Suppl 4, S9鈥揝13 (2008). CrossRef
  39. Ruggeri, Z. M., The role of von Willebrand factor in thrombus formation. / Thromb. Res., 120Suppl 1, S5鈥揝9 (2007). CrossRef
  40. Sadler, J. E., Biomedicine. Contact鈥攈ow platelets touch von Willebrand factor. / Science, 297, 1128鈥?129 (2002). CrossRef
  41. Sadler, J. E., Budde, U., Eikenboom, J. C., Favaloro, E. J., Hill, F. G., Holmberg, L., Ingerslev, J., Lee, C. A., Lillicrap, D., Mannucci, P. M., Mazurier, C., Meyer, D., Nichols, W. L., Nishino, M., Peake, I. R., Rodeghiero, F., Schneppenheim, R., Ruggeri, Z. M., Srivastava, A., Montgomery, R. R., and Federici, A. B., Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. / J. Thromb. Haemost., 4, 2103鈥?114 (2006). CrossRef
  42. Scarborough, R. M., Kleiman, N. S., and Phillips, D. R., Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? / Circulation, 100, 437鈥?44 (1999). CrossRef
  43. Siller-Matula, J. M., Krumphuber, J., and Jilma, B., Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. / Br. J. Pharmacol., 159, 502鈥?17 (2010). CrossRef
  44. Sostres, C. and Lanas, A., Gastrointestinal effects of aspirin. / Nat. Rev. Gastroenterol. Hepatol., 8, 385鈥?94 (2011). CrossRef
  45. Spiel, A. O., Mayr, F. B., Ladani, N., Wagner, P. G., Schaub, R. G., Gilbert, J. C. and Jilma, B., The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated / ex vivo platelet function in acute myocardial infarction. / Platelets, 20, 334鈥?40 (2009). CrossRef
  46. Varga-Szabo, D., Pleines, I., and Nieswandt, B., Cell adhesion mechanisms in platelets. / Arterioscler. Thromb. Vasc. Biol., 28, 403鈥?12 (2008). CrossRef
  47. Vischer, U. M., von Willebrand factor, endothelial dysfunction, and cardiovascular disease. / J. Thromb. Haemost., 4, 1186鈥?193 (2006). CrossRef
  48. von Willebrand, E. A., Heredit盲rpseudohemofili. / Fin. Laekaresaellsk Hand. 68, 87鈥?12. (1926).
  49. Wagner, D. D. and Burger, P. C., Platelets in inflammation and thrombosis. / Arterioscler. Thromb. Vasc. Biol., 23, 2131鈥?137 (2003). CrossRef
  50. Weitz, J. I., Hirsh, J., and Samama, M. M., New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). / Chest, 133, 234S鈥?56S (2008). CrossRef
  51. Yago, T., Lou, J., Wu, T., Yang, J., Miner, J. J., Coburn, L., L贸pez, J. A., Cruz, M. A., Dong, J. F., McIntire, L. V., McEver, R. P., and Zhu, C., Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. / J. Clin. Invest., 118, 3195鈥?207 (2008).
  
• 作者单位：Ok-Nam Bae (1) (2)
  
  1. College of Pharmacy, Hanyang University, Gyeonggi-do, 426-791, Korea
  2. College of Pharmacy, Hanyang University, Ansan, 426-791, Korea
  
• ISSN：1976-3786

文摘

Excessive activation of platelets is a causative factor for thrombotic diseases such as acute coronary syndrome or stroke, and various anti-platelet drugs were developed. Aspirin and clopidogrel have been used as gold standards for anti-platelet therapies, however, their clinical limitations including bleeding problem have increased the demand driving development of novel anti-platelet drugs with new targets. Among several activating pathways leading to platelet aggregation, the interaction between von Willebrand factor (vWF) and glycoprotein Ib, which mainly occurs under high shear stress in arterioles, is recently suggested to be a new promising target. The anti-thrombotic efficacy of anti-vWF agents, such as ARC1779, has been proved in several preclinical and clinical studies. Here, we will discuss the potential benefits of targeting vWF as a novel antiplatelet therapy, providing an insight into the role of vWF in increased thrombotic risk.